ReviewCurrent cardiology reviews2023
Role of β-blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction.
Review in Current cardiology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Associations between death anxiety, health literacy, and illness perception in Iranian individuals with heart failure an analytical cross sectional study.Discover mental health · 2026Article
- Beta-blocker therapy after myocardial infarction: an umbrella review.EClinicalMedicine · 2026Article
- A comprehensive review of ischemic heart disease: pathophysiology, current treatments, natural products-based therapies, and nanotherapeutics.Frontiers in pharmacology · 2026Review
- Chemogenetic activation of cholinergic intrinsic cardiac ganglia improves border zone oxygenation and reduces arrhythmias during acute local ischemia.Frontiers in cardiovascular medicine · 2026Article
- Association of Long-Term Oral β-Blocker Use With Cardiac Troponin I and B-Type Natriuretic Peptide in Septic Myocardial Injury: A Retrospective Cohort Study.Health science reports · 2025Article
- Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches.Heart failure reviews · 2025Review
- Cardioprotection Reloaded: Reflections on 40 Years of Research.Antioxidants (Basel, Switzerland) · 2025Review
- Longitudinal Myocardial Deformation as an Emerging Biomarker for Post-Traumatic Cardiac Dysfunction.Life (Basel, Switzerland) · 2025Review
- Empagliflozin and Right-Sided Heart Failure: A Comprehensive Review of Emerging Evidence and Clinical Perspectives.Cureus · 2025Review
- Relationship between β-receptor blocker and atrial fibrillation in patients with heart failure: an observational study based on MIMIC IV database.BMC cardiovascular disorders · 2025Observational
- The Role of Infarct Border Zone Remodelling in Ventricular Arrhythmias: Bridging Basic Research and Clinical Applications.Journal of cellular and molecular medicine · 2025Review
- Uncovering Hippo pathway-related biomarkers in acute myocardial infarction via scRNA-seq binding transcriptomics.Scientific reports · 2025Article
- Advances in the study of Wellens syndrome.The Journal of international medical research · 2025Review
- Beta-Blockers as an Immunologic and Autonomic Manipulator in Critically Ill Patients: A Review of the Recent Literature.International journal of molecular sciences · 2024Review
- 3-Nitroatenolol: First Synthesis, Chiral Resolution and Enantiomers' Absolute Configuration.Molecules (Basel, Switzerland) · 2024Article
- The Beta-blocker chronicle: From past principles to present practice - Implications for the Indian subcontinent.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-blockers have been widely utilized as a part of acute myocardial infarction (AMI) treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following myocardial infarction have a higher chance of surviving. Although many patients benefited from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction, chronic pulmonary disease, and elderly people. In individuals with the post-acute coronary syndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of betablocker therapy is still unknown. There is also no time limit for those without angina and those who do not need β-blockers for arrhythmia or hypertension. Interestingly, β-blockers have been prescribed for more than four decades. The novel mechanism of action on cellular compartments has been found continually, which opens a new way for their potential application in cardiac failure and other cardiac events like post-myocardial infarction. Here, in this review, we studied β-blocker usage in these circumstances and the current recommendations for β-blocker use from clinical practice guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.